Moderna Settles LNP Patent Suit for $2.25B

At the heart of the dispute is the lipid nanoparticle (LNP) delivery system, a microscopic fatty bubble that protects the delicate mRNA and transports it into human cells. Without this LNP shield, the mRNA in the vaccine would be quickly destroyed by the body and rendered ineffective. Arbutus Biopharma, a small Canadian firm, had been developing and patenting this LNP technology for nearly two decades. Their work led to the first-ever FDA-approved RNA-LNP therapeutic, a drug called Onpattro, which was approved in 2018. Moderna was aware of Arbutus's patents and had previously licensed the LNP technology for other research projects. However, for its COVID-19 vaccine, Moderna used the technology without a license, prompting the lawsuit from Arbutus and its licensee, Genevant Sciences. The settlement includes a $950 million upfront payment to Genevant and Arbutus, with a potential additional $1.3 billion depending on the outcome of an appeal concerning government liability. If the full amount is paid, it would represent the largest disclosed patent settlement in the history of the pharmaceutical industry. This case highlights the critical role of intellectual property (IP) law in the life sciences. Careers in this field involve protecting inventions and ensuring that innovators are compensated. Professionals with a background in biology are needed as patent agents and attorneys to navigate the complex intersection of science and law. For those interested in the tech side of life sciences, this illustrates how a deep understanding of biology is crucial for roles that aren't at the lab bench. A patent attorney in biotech, for example, needs to understand the science deeply to write and defend a patent on a complex technology like LNP delivery. The legal battles over mRNA vaccine technology are not over. Genevant and Arbutus are also in an ongoing patent infringement lawsuit against Pfizer and BioNTech over their COVID-19 vaccine, which also utilizes LNP technology.